News
Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...
A long-term follow-up of early total therapy trials suggests that up to one-third of patients with newly diagnosed multiple ...
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...
Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in ...
Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung ...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced today that the Phase 3 IMforte trial has established a new milestone in the ...
4d
MedPage Today on MSNSurvival in Unresectable Pancreatic Cancer Improved With Tumor Treating FieldsCHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...
5d
News-Medical.Net on MSNCombination treatment extends progression-free survival in advanced skin cancerIn patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...
7d
Clinical Trials Arena on MSNASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRCPhase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.
For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, the oral proteolysis-targeting chimera ER degrader, vepdegestrant, ...
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results